文献速递结核与非结核分枝杆菌病毒性肝炎

静脉N-乙酰半胱氨酸治疗抗结核药物性肝损伤的随机对照试验

A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.
PubMed 文献 · Clin Infect Dis · 2021-01-01

NAC未缩短ALT降至100 U/L以下的时间,但显著缩短住院时间(中位9天 vs 18天,HR 1.73,95%CI 1.13-2.65),总死亡率14%且组间无差异。

要点

  • NAC未缩短AT-DILI患者ALT降至100 U/L以下的时间。
  • NAC显著缩短住院时间(中位9天 vs 18天,HR 1.73)。
  • NAC组5例因不良反应提前停止输注,包括恶心呕吐、过敏反应等。

核心结论

  • 静脉NAC未缩短AT-DILI患者ALT降至100 U/L以下的时间,但显著缩短住院时间。
  • 总死亡率为14%,且在不同研究组间无差异。
  • 作者建议在AT-DILI管理中考虑使用NAC。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,评估静脉NAC在住院成人AT-DILI患者中的疗效。
  • 主要终点为血清ALT降至100 U/L以下的时间。

主要发现

  • NAC组ALT降至100 U/L以下的中位时间为7.5(6-11)天,安慰剂组为8(5-13)天。
  • NAC组中位出院时间9(6-15)天,短于安慰剂组的18(10-25)天(HR 1.73;95%CI 1.13-2.65)。
  • 总死亡率为14%,按研究组无差异。
  • 5例接受NAC的参与者因不良反应提前停止输注:恶心和呕吐3例、过敏反应1例、滴注部位疼痛1例。

临床怎么用

  • 对于AT-DILI住院患者,可考虑使用静脉NAC以缩短住院时间。
  • 使用NAC时需监测不良反应,如恶心呕吐、过敏反应和输注部位疼痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver injury is a common complication of anti-tuberculosis therapy. N-acetylcysteine (NAC) used in patients with paracetamol toxicity with limited evidence of benefit in liver injury due to other causes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy of intravenous NAC in hospitalized adult patients with anti-tuberculosis drug-induced liver injury (AT-DILI). The primary endpoint was time for serum alanine aminotransferase (ALT) to fall below 100 U/L. Secondary endpoints included length of hospital stay, in-hospital mortality, and adverse events. RESULTS: Fifty-three participants were randomized to NAC and 49 to placebo. Mean age was 38 (SD±10) years, 58 (57%) were female, 89 (87%) were HIV positive. Median (IQR) serum ALT and bilirubin at presentation were 462 (266-790) U/L and 56 (25-100) μmol/L, respectively. Median time to ALT <100 U/L was 7.5 (6-11) days in the NAC arm and 8 (5-13) days in the placebo arm. Median time to hospital discharge was shorter in the NAC arm (9 [6-15] days) than in the placebo arm (18 [10-25] days) (HR, 1.73; 95% CI, 1.13-2.65). Mortality was 14% overall and did not differ by study arm. The study infusion was stopped early due to an adverse reaction in 5 participants receiving NAC (nausea and vomiting [3], anaphylaxis [1], pain at drip site [1]). CONCLUSIONS: NAC did not shorten time to ALT <100 U/L in participants with AT-DILI, but significantly reduced length of hospital stay. NAC should be considered in management of AT-DILI. CLINICAL TRIALS REGISTRATION: South African National Clinical Trials Registry (SANCTR: DOH-27-0414-4719).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Moosa MS, Maartens G, Gunter H, et al. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clin Infect Dis. 2021. PMID: 32845997. doi:10.1093/cid/ciaa1255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。